Privacy Policy

Genelux Privacy Policy

(Effective: July 9, 2021)


Your privacy is important to Genelux, Inc. (“Genelux” or “we” or “us”), and this Privacy Policy describes the manner in which we handle personal information collected in connection with its public website, (the “Site”).  Genelux has established this Privacy Policy to protect the content of the Site, including all information provided by Site users, from unauthorized access, disclosure or release. In this Privacy Policy, “personal information” means information that identifies, or may be used to identify, an individual, including, but not limited to, name, address, phone or email. If you have any questions or concerns regarding this Privacy Policy, you may contact us at


The Information We Collect

In general, you can browse the Site without telling us who you are or revealing any personal information about yourself.  We may collect internet protocol (IP) address, browser type, internet service provider, referring/exit pages, platform type, date/time stamp and number of clicks to analyze trends, administer the site, track user’s movement in the aggregate and gather broad demographic information for aggregate use. Our objective is to monitor the quality of the user experiences on the Site. No personal information is gathered in such a process, and we do not link any such automatically collected data to any personal information.


If you choose to contact us and provide personal information, you are no longer anonymous to us, and we will utilize your personal information to respond to your inquiry. We do not create or maintain profiles of Site users, and we do not collect or maintain personal information for resale purposes.


To respond to a Site user’s request, we may share relevant personal information with our employees, advisors and/or service providers. We require our third-party service providers to treat your personal information in accordance with applicable laws.


Genelux reserves the right to disclose personal information if required by law, subpoena or other court order, and, to the extent permitted by applicable law, to the extent necessary to exercise the legal rights or protect the safety of Genelux and its employees and agents.



This Site is not intended for, or designed to attract, children under the age of 13. As noted above, we do not collect personal information, including an individual’s age. If a parent or guardian becomes aware that its child has provided us with personal information, such parent or guardian should contact us, and we will take commercially reasonable steps to delete such personal information from our database within a reasonable time.


Communications from the Site

The only communications resulting from the Site are responses to visitor requests for additional information. Communications may be via phone, email or postal mail.



We follow generally accepted industry standards to protect the personal information submitted to us from loss, misuse or unauthorized access, alteration, destruction or disclosure. However, no method of transmission over the Internet, or method of electronic storage, is 100% secure.  Therefore, while we strive to use commercially reasonable means to protect your personal information, we cannot guarantee its absolute security.


Links to other sites

The Site contains links to other sites that are not owned or controlled by Genelux.  Please be aware that we are not responsible for the privacy policies of such other sites.  We encourage you to be aware when you leave the Site and to read the privacy policies of each and every website that collects personal information.  This Privacy Policy applies only to information collected by this Site.



Any updated versions of this Privacy Policy will be posted on this page and shall be effective upon that posting. We reserve the right to modify this Privacy Policy at any time, so please review it frequently.

Expanded Access Policy

Outside of our clinical trials, we may provide physician-requested expanded access to its investigational products under limited situations. The request for access to a Genelux investigational drug will be considered only if all the following criteria are met.


  • The patient has a serious or life-threatening disease or condition with no comparable or satisfactory alternative therapies
  • The patient is not eligible for or unable to participate in a clinical trial
  • The investigational drug is currently in clinical development with sufficient evidence of safety and effectiveness for patient’s specific condition
  • A benefit-risk analysis suggests that the benefit from using of the investigational drug outweighs the known or anticipated risks based on evolving clinical data
  • We have adequate supply of investigational drug


If the investigational drug is approved by a regulatory agency for commercial use, including provisional approval, existing expanded access programs will be phased out or modified accordingly.


Patients interested in seeking an expanded access to a Genelux investigative drug should talk to their physician. All requests must be made by the patient’s treating physician by email at We will, in general, acknowledge receipt of a request for expanded access within five business days. We may ask for more detailed information to fully evaluate a request.


The request for access to an investigative drug can only be considered if the requesting physician agrees to obtain applicable regulatory and ethics committee approvals. We may deny access if the treating physician cannot guarantee an appropriate storage and handling of the investigative drug, which typically requires a temperature controlled deep freezer and follows Biosafety Level 2 safety procedures and precautions. The treating physician must agree to comply with regulatory obligations, including safety monitoring and reporting.


For more information on expanded access from the FDA, click here.